At Kyowa Kirin, patients are our North Star. This #XLHAwarenessDay, we recognize the community who help to inform and inspire our work. Thanks to your input, we better understand how best to support your needs.
This is our pledge to you: https://t.co/TfgHeyspYc
@sandymorris333@KylanMorris1 Heartbroken to hear this news. Sandy was a force. Always fighting to shape a better future. Always willing to give her support to those who needed it. To the Morris family, our hearts are with you. May her memory be a blessing ❤️ #belikeSandy
@united suprise, surprise I'm once again forced to check my bag when there's plenty of overhead space. Confirmed with on plane attendant that flight showed available space. Seriously, WTF. 3x in a row now.
@united 2nd time in a week gate agents made me check bag when there's plentiful of room in overhead. Shall we take bets on whether bag makes my 30 min connection?
@RaviBhalla@CityofHoboken When you try to take the survey you are unable to rank as directed. Once you select one, the rest autopopulates. Assuming this is not what you wanted!
We understand how important it is to raise awareness for the millions living with #rarediseases. For 30+ years we’ve pursued scientific discoveries to help address unmet medical needs. Today our employees join the community to support #ShowyourStripes for #rarediseasaeday
I’m proud to say that the Senate has sent the ACT for ALS Act to President Biden’s desk to be signed into law.
This historic legislation will transform research into ALS and spur the discovery of new treatments and cures for ALS patients.
Our own Lucianna DiMeglio, MSN, ANP-BC, AOCN spoke with Prof Pierluigi Porcu, MD, from @KimmelCancerCtr about the lack of diversity in clinical research and why it’s so important, particularly in rare cancers like #CTCL. #BloodCancerAwarenessMonth
https://t.co/FvPExCWJ1l
#Sponsored by @KyowaKirin_US:
In honor of #BloodCancerAwarenessMonth, a coach shares how a rare cancer changed his life and what it took to get him back in the game.
Read more here: https://t.co/LLcB3jgdAH
Health equity is important, particularly in CTCL (cutaneous T-cell lymphoma) where the prevalence is higher among African Americans. Learn more: https://t.co/bJsI9Do1ZT
#LookDeeper#BloodCancerAwarenessMonth
Because CTCL (cutaneous T-cell lymphoma) is rare, it’s important to raise awareness so those in need are accurately diagnosed and treated. Learn more: https://t.co/6nSgEwSUdg
#LookDeeper#BloodCancerAwarenessMonth
Thank you @alsadvocacy for this fierce op-ed in STAT. You're absolutely right, pALS and cALS know they've been played. #ALS is 100% fatal. Real people are #DyingWaiting for industry and @US_FDA to act with urgency. #drugsinbodies
https://t.co/qTvcC2V4oO via @statnews
@Mayuri_Saxena is fighting for her life. Yet she continues to work tirelessly using her eye gaze device advocating for everyone with #ALS, fighting for everyone's life. If you can, please help this warrior in her fight and share with your network.
https://t.co/37mSLFVN2k
This is what denying access to #tofersen now -- not in 3 months, not in 6 months -- looks like for people with fast-progressing SOD1 ALS. PALS are #DyingWaiting and need #DrugsinBodies now. TY @Mayuri_Saxena for sharing your truth.
@Chance4Lisa @US_FDA@biogen
My husband and I fought for continued access to treatment and to improve an archaic regulatory pathway. He died waiting for change, writes Nicole Cimbura https://t.co/w1lklYHptl
We need EAPs for people living w/ ALS today. I made this simplistic visual for Biogen but can easily customize for any ALS trial. We can put this in the consent form pkg for every trial so there are no more misunderstandings. If you qualify for a trial, you don’t qualify for EAP.
This paper should be required reading for any biopharma exec, regulator or advocate/advocacy group. The focus right now is on one brave woman, @Chance4Lisa, and one company, @biogen, but the core issue is larger and fundamental to who we are. /1